The latest from CDMOs, CMOs, and suppliers featuring Delpharm, Almac Group, Singota, Enzene and Benuvia Operations.

Chemicals/Chemical API Manufacturing
* CordenPharma Investing $536-M in New Peptide Mfg Facility in Switzerland
Biologics Manufacturing
* Enzene Receives GMP Certification from EU
Formulation Development/Drug Product Manufacturing
* Delpharm in $140-M Upgrade of Canadian Sterile Mfg Facility
* Almac Opens $84-M Oral Drug Mfg Facility
* Singota Solutions Opens New Facility for Sterile Drug-Product Storage
General
* Benuvia Receives GMP Certification from Brazilian Regulatory Authorities

---

Chemicals/Chemical API Manufacturing

CordenPharma Investing $536-M in New Peptide Mfg Facility in Switzerland
CordenPharma has finalized plans to establish a EUR 500-million ($536-million) peptide manufacturing facility in Switzerland located at Getec Park in Muttenz. The company  announced the news earlier this month (March 5, 2025).

The investment will feature multiple manufacturing lines capable of supporting small, medium, and large-scale peptide production with small- to large-scale solid phase peptide synthesis (SPPS) reactors for glucagon-like peptide-1 (GLP-1) and non-GLP-1 peptide projects – with a total SPPS reactor capacity of more than 5,000 L. The new facility will feature advanced automation, digitalization, and innovative peptide production technologies. The main construction and qualification phase is taking place between 2025 and 2027, and commercial activities will begin in the first half of 2028.

In the company’s Boulder, Colorado US facility, both expansions to existing lines and the construction of a new greenfield production area have already begun in parallel to the Switzerland initiative. The expansion will more than double the existing SPPS reactor capacity at CordenPharma Colorado by adding an additional 25,000 L of SPPS capacity, making total reactor capacity of >42,000L by 2028.

Source: CordenPharma

---

Biologics Manufacturing

Enzene Receives GMP Certification from EU
Enzene, a Pune, India-based CDMO of biologics, announced earlier this month (March 2025) that its two facilities in Pune, India, have received EU GMP certification to provide commercial-scale microbial and mammalian drug-substance supply and drug-product fill–finish and packaging. The company operates facilities in Pune, India, and New Jersey in the US.

Source: Enzene

---

Formulation Development/Drug Product Manufacturing

Delpharm in $140 M Upgrade of Canadian Sterile Mfg Facility
Delpharm, a CDMO of drug products, has reached an agreement with the government of Canada to modernize its injectable manufacturing facility in Boucherville, Quebec, Canada. The facility manufactures 65 million units primarily for North America and specializes in the production of sterile drugs packaged in vials and ampuls.

The modernization plan represents a total investment exceeding CAD$200 million (US$140 million) and will preserve over 500 jobs in Quebec. Scheduled to run until 2031, the plan includes expanding the site, installing a new filling line, and upgrading existing equipment to comply with new Health Canada standards. Ultimately, 95% of the equipment will be replaced.

Source: Delpharm

---

Almac Opens $84-M Oral Drug Mfg Facility
Almac Group, a Craigavon, Northern Ireland-based CDMO of drug substances and drug products, has opened a new £65 million ($84 million)  oral dosage commercial manufacturing facility at its global headquarters in Craigavon, Northern Ireland. The company made the announcement earlier this month (March 2025).

The new 100,000-square-foot facility enhances existing capabilities in commercial manufacture of oral dose treatments for a variety of therapeutic areas and includes an extension to current production scales of potent and highly potent drug products.

Construction of the building was completed in late 2024 and following successful completion of validation activities, manufacture of GMP batches will commence in the regulatory approved facility.

Source: Almac

---

Singota Solutions Opens New Facility for Sterile Drug-Product Storage
Singota Solutions, a CDMO of sterile drug products and supply-chain services, has opened a new 100,000-square foot facility in Balerna, Switzerland. Configured for advanced, precision temperature-controlled storage, the facility offers 4,000 pallet positions in the storage temperature conditions of +15–25°C and future capacity for storage at -20°C and at +5°C, projected for late 2025. The new facility spans three floors and includes a rooftop solar power system capable of supplementing energy supplied by the regional grid.

Source: Singota Solutions

---

General

Benuvia Receives GMP Certification from Brazilian Regulatory Authorities
Benuvia, a CDMO, has received a Good Manufacturing Practices (GMP) certification from Brazil’s National Health Surveillance Agency (ANVISA). The company provides end-to-end development and manufacturing services for active pharmaceutical ingredients and finished dosage products and has expertise in cannabinoids, psychedelics, and other controlled substances. Benuvia operates an 83,000-square-foot manufacturing facility in Round Rock, Texas that can produce Schedule I-V compounds.

Source: Benuvia